收费全文 | 106347篇 |
免费 | 9004篇 |
国内免费 | 2143篇 |
耳鼻咽喉 | 872篇 |
儿科学 | 2457篇 |
妇产科学 | 1346篇 |
基础医学 | 5819篇 |
口腔科学 | 5304篇 |
临床医学 | 10669篇 |
内科学 | 13952篇 |
皮肤病学 | 1901篇 |
神经病学 | 6820篇 |
特种医学 | 2484篇 |
外国民族医学 | 31篇 |
外科学 | 10534篇 |
综合类 | 17264篇 |
现状与发展 | 12篇 |
一般理论 | 4篇 |
预防医学 | 8615篇 |
眼科学 | 2708篇 |
药学 | 9256篇 |
164篇 | |
中国医学 | 9521篇 |
肿瘤学 | 7761篇 |
2024年 | 374篇 |
2023年 | 1907篇 |
2022年 | 3240篇 |
2021年 | 4593篇 |
2020年 | 4699篇 |
2019年 | 3844篇 |
2018年 | 3600篇 |
2017年 | 3919篇 |
2016年 | 4172篇 |
2015年 | 3943篇 |
2014年 | 7183篇 |
2013年 | 9650篇 |
2012年 | 6823篇 |
2011年 | 7165篇 |
2010年 | 6018篇 |
2009年 | 5309篇 |
2008年 | 4765篇 |
2007年 | 4995篇 |
2006年 | 4455篇 |
2005年 | 3841篇 |
2004年 | 3223篇 |
2003年 | 2829篇 |
2002年 | 2407篇 |
2001年 | 1955篇 |
2000年 | 1667篇 |
1999年 | 1343篇 |
1998年 | 1111篇 |
1997年 | 1005篇 |
1996年 | 865篇 |
1995年 | 751篇 |
1994年 | 704篇 |
1993年 | 635篇 |
1992年 | 519篇 |
1991年 | 490篇 |
1990年 | 369篇 |
1989年 | 339篇 |
1988年 | 314篇 |
1987年 | 285篇 |
1986年 | 269篇 |
1985年 | 370篇 |
1984年 | 271篇 |
1983年 | 192篇 |
1982年 | 246篇 |
1981年 | 190篇 |
1980年 | 165篇 |
1979年 | 136篇 |
1978年 | 89篇 |
1977年 | 72篇 |
1976年 | 57篇 |
1975年 | 38篇 |
Method: First, persons assessed for admittance in 2005–2011 (n?=?127) were categorized into four trajectory groups based on whether they were admitted or denied (n?=?19), discharged (n?=?31), readmitted (n?=?21) or had been undergoing OMT without interruption (n?=?56). Second, 99 of these, the analytical sample, were interviewed at follow-up using (a) the Addiction Severity Index (ASI) for seven problem-areas and housing, and (b) self-rated change in 11 problem areas. The ASI was compared to baseline interviews after 55 months (mean). Third, outcomes within groups was studied in relation to alternative interventions.
Results: Within the analytical sample, those denied OMT showed no improvements at group level, those discharged had some improvements, more if readmitted than if not and those with uninterrupted OMT showed the most comprehensive improvements. Those outside OMT, denied and discharged, had considerable mortality risks related to ongoing drug use, especially in lack of well-planned alternative interventions.
Conclusion: Improvements strongly relate to access to OMT. This study underscores that access to OMT improves the situation in all areas investigated and decreases the risk for drug-related death. It underscores the importance of two major risk situations, i.e. being denied OMT and being discharged. 相似文献
Areas covered: The many tools developed to measure disease activity in RA, from composite scores and patient-reported outcomes, to laboratory markers and imaging are discussed, with a focus on their utility in guiding therapy and assessing response. The complex issues in measuring disease activity in RA, whether in clinical trials or normal clinical practice, and in the context of national guidelines and recommendations, available time, and resources are considered.
Expert commentary: The key to effective management of RA is the rapid suppression of inflammation, ideally to remission, with maintenance of such remission. The aim is to prevent disability and maximize quality of life. Central to this is the ability to determine disease activity (potentially open to suppression) as opposed to damage (irreversible). A variety of measures are currently available, allowing better assessment of response to treatment. In the future, the development of predictive biomarkers allowing targeting of drugs may revolutionize this field and render the tools of today redundant. 相似文献